CN1089469A - 用于持续释放药物的传送装置的二相基材 - Google Patents
用于持续释放药物的传送装置的二相基材 Download PDFInfo
- Publication number
- CN1089469A CN1089469A CN93118244A CN93118244A CN1089469A CN 1089469 A CN1089469 A CN 1089469A CN 93118244 A CN93118244 A CN 93118244A CN 93118244 A CN93118244 A CN 93118244A CN 1089469 A CN1089469 A CN 1089469A
- Authority
- CN
- China
- Prior art keywords
- base material
- medicine
- pharmaceutical formulation
- release pharmaceutical
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 230000002045 lasting effect Effects 0.000 title claims description 16
- 239000011159 matrix material Substances 0.000 title abstract description 9
- 239000012071 phase Substances 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 19
- 239000002674 ointment Substances 0.000 claims abstract description 17
- 229920001600 hydrophobic polymer Polymers 0.000 claims abstract description 14
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 229910052909 inorganic silicate Inorganic materials 0.000 claims abstract description 12
- 239000008346 aqueous phase Substances 0.000 claims abstract description 6
- 238000010521 absorption reaction Methods 0.000 claims abstract description 5
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- -1 fatty acid ester Chemical class 0.000 claims description 31
- 229920001296 polysiloxane Polymers 0.000 claims description 22
- 235000012241 calcium silicate Nutrition 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 13
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 230000036571 hydration Effects 0.000 claims description 10
- 238000006703 hydration reaction Methods 0.000 claims description 10
- 239000002270 dispersing agent Substances 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 claims description 6
- WXLPKTIAUMCNDX-UHFFFAOYSA-N 2h-pyran-3-ol Chemical compound OC1=CC=COC1 WXLPKTIAUMCNDX-UHFFFAOYSA-N 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000002798 polar solvent Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 4
- 229960004217 benzyl alcohol Drugs 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- 239000004821 Contact adhesive Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 2
- 229960003727 granisetron Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims 1
- 229910000323 aluminium silicate Inorganic materials 0.000 claims 1
- 125000005313 fatty acid group Chemical group 0.000 claims 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims 1
- 239000000391 magnesium silicate Substances 0.000 claims 1
- 235000019792 magnesium silicate Nutrition 0.000 claims 1
- 229910052919 magnesium silicate Inorganic materials 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 5
- 230000002500 effect on skin Effects 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 33
- 239000011230 binding agent Substances 0.000 description 20
- 239000010410 layer Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 10
- 208000028659 discharge Diseases 0.000 description 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 4
- 229920002367 Polyisobutene Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 229960000201 isosorbide dinitrate Drugs 0.000 description 4
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 4
- 229940055577 oleyl alcohol Drugs 0.000 description 4
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 4
- 235000010603 pastilles Nutrition 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 229920002633 Kraton (polymer) Polymers 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical class O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Substances C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 description 1
- WHSXTWFYRGOBGO-UHFFFAOYSA-N 3-methylsalicylic acid Chemical compound CC1=CC=CC(C(O)=O)=C1O WHSXTWFYRGOBGO-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical group CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- JHLNERQLKQQLRZ-UHFFFAOYSA-N calcium silicate Chemical compound [Ca+2].[Ca+2].[O-][Si]([O-])([O-])[O-] JHLNERQLKQQLRZ-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 150000003151 propanoic acid esters Chemical class 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95663592A | 1992-10-05 | 1992-10-05 | |
| US956,635 | 1992-10-05 | ||
| US08/056,076 US5989586A (en) | 1992-10-05 | 1993-04-30 | Two-phase matrix for sustained release drug delivery device |
| US056,076 | 1993-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1089469A true CN1089469A (zh) | 1994-07-20 |
Family
ID=26734946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93118244A Pending CN1089469A (zh) | 1992-10-05 | 1993-10-05 | 用于持续释放药物的传送装置的二相基材 |
Country Status (14)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457095C (zh) * | 2001-05-08 | 2009-02-04 | 施瓦茨制药有限公司 | 用于治疗帕金森氏病的改良经皮治疗系统 |
| CN100558350C (zh) * | 2002-07-30 | 2009-11-11 | 施瓦茨制药有限公司 | 改良透皮递药系统 |
| CN102172351B (zh) * | 2001-05-08 | 2013-07-17 | 优时比制药有限公司 | 引起高罗替高汀血浆水平的用于治疗帕金森氏病的透皮治疗系统 |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989586A (en) * | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
| US5383873A (en) * | 1992-12-09 | 1995-01-24 | Regents Of The University Of Minnesota | Smooth muscle chemical pacemaker |
| AU4761196A (en) * | 1995-01-19 | 1996-08-07 | Cygnus, Inc. | Polymer adhesive formulation containing sorbent particles |
| US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
| DE69715049T2 (de) * | 1996-02-07 | 2003-04-03 | Kissei Pharmaceutical Co., Ltd. | Tranilast enthaltendes externum und verfahren zu dessen herstellung |
| JPH10167956A (ja) * | 1996-12-11 | 1998-06-23 | Hisamitsu Pharmaceut Co Inc | セロトニン受容体拮抗薬含有経皮投与製剤 |
| US6119036A (en) * | 1997-03-26 | 2000-09-12 | The Board Of Regents Of The University Of Oklahoma | Iontophoretic transdermal delivery device |
| AU3170697A (en) * | 1997-05-30 | 1998-12-30 | Minnesota Mining And Manufacturing Company | Transdermal drug delivery device for the delivery of tropisetron or granisetron |
| DE69910743T2 (de) * | 1998-02-25 | 2004-07-08 | The Government Of The United States, As Represented By The Secretary Of The Army | Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp-ribosylating-exotoxin induzierten immunantwort |
| DE19814087A1 (de) | 1998-03-30 | 1999-10-14 | Lohmann Therapie Syst Lts | Feuchtigkeitsaktivierbares therapeutisches System |
| DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE19827732A1 (de) * | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
| ES2372592T3 (es) * | 1999-04-08 | 2012-01-24 | Intercell Usa, Inc. | Formulación seca para la inmunización transcutánea. |
| DE19929197A1 (de) * | 1999-06-25 | 2000-12-28 | Novosis Pharma Ag | Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung |
| US20040109874A1 (en) * | 1999-11-10 | 2004-06-10 | Powderject Vaccines, Inc. | Induction of mucosal immunity by vaccination via the skin route |
| US6562369B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers |
| US6562370B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers |
| US6602912B2 (en) | 2000-06-30 | 2003-08-05 | Dermatrends, Inc. | Transdermal administration of phenylpropanolamine |
| US20030104041A1 (en) * | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US6562368B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers |
| US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| US6719997B2 (en) | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
| US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
| US6673363B2 (en) * | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
| US6565879B1 (en) | 1999-12-16 | 2003-05-20 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers |
| US6582724B2 (en) | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
| US6645520B2 (en) | 1999-12-16 | 2003-11-11 | Dermatrends, Inc. | Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers |
| KR100393478B1 (ko) * | 2000-03-29 | 2003-08-06 | 주식회사종근당 | 자가유화 매트릭스형 경점막·경피흡수제제 |
| DE10015783C2 (de) * | 2000-03-30 | 2003-12-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung |
| US20050042194A1 (en) * | 2000-05-11 | 2005-02-24 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
| DE10027258C1 (de) * | 2000-05-31 | 2001-10-31 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit okklusiver wirkstoffhaltiger Schicht und nicht-okklusiver Rückschicht |
| DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| ATE319428T1 (de) | 2000-12-07 | 2006-03-15 | Univ Utrecht Holding Bv | Zusammensetzung zur behandlung von entzündlichen erkrankungen |
| DE10136784A1 (de) * | 2001-07-27 | 2003-02-20 | Lohmann Therapie Syst Lts | Darreichungsformen mit wirkstoffhaltigen Partikeln, zur Anwendung auf der Haut oder Schleimhaut |
| EP1427397B1 (en) * | 2001-09-10 | 2008-02-13 | F. Hoffmann-La Roche Ag | Oily thixotropic formulations |
| US7273619B2 (en) * | 2002-01-17 | 2007-09-25 | Samyang Corporation | Transdermal composition of an antivomiting agent |
| US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| CA2489347A1 (en) * | 2002-06-20 | 2003-12-31 | Amnon Sintov | Transdermal drug delivery system |
| EP1386605A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system for the administration of rotigotine |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| DE10234673B4 (de) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| IL152573A (en) * | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | A system for the transmission through the skin of a medical preparation against vomiting and nausea |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| PT1426049E (pt) | 2002-12-02 | 2005-09-30 | Sanol Arznei Schwarz Gmbh | Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson |
| DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
| GB0302662D0 (en) | 2003-02-05 | 2003-03-12 | Strakan Ltd | Transdermal granisetron |
| DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| US20050118246A1 (en) * | 2003-10-31 | 2005-06-02 | Wong Patrick S. | Dosage forms and layered deposition processes for fabricating dosage forms |
| EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
| US7262145B2 (en) * | 2004-04-23 | 2007-08-28 | Kennametal Inc. | Whisker-reinforced ceramic containing aluminum oxynitride and method of making the same |
| US20070264319A1 (en) * | 2004-09-01 | 2007-11-15 | Lebo David B | Transdermal Antiemesis Delivery System, Method and Composition Therefor |
| SE528360C2 (sv) * | 2004-09-10 | 2006-10-24 | Doxa Ab | Resorberbara keramiska kompositioner avsedda för medicinska implantat |
| WO2006039532A2 (en) * | 2004-09-29 | 2006-04-13 | Schwarz Pharma, Inc. | Transdermal therapeutic system for parkinson’s disease |
| US20060263421A1 (en) * | 2005-05-18 | 2006-11-23 | Abeille Pharmaceuticals Inc | Transdermal Method and Patch for Nausea |
| KR101207553B1 (ko) | 2005-06-02 | 2012-12-03 | (주)씨앤팜 | 금속 이중층 수산화물을 포함하는 생체 주사제용 약물 담체 |
| JP2009509675A (ja) * | 2005-09-30 | 2009-03-12 | Tti・エルビュー株式会社 | 新規薬学的ビヒクルを用いる経皮薬剤送達システム、装置、及び方法 |
| JP5005916B2 (ja) * | 2005-12-09 | 2012-08-22 | スリーエム イノベイティブ プロパティズ カンパニー | 皮膚粘着剤用剥離剤組成物 |
| KR101402592B1 (ko) * | 2006-03-06 | 2014-06-17 | 에스케이바이오팜 주식회사 | 피록시캄-무기물 복합체를 포함하는 경피투여 조성물 및이를 이용한 패치시스템 |
| WO2009086840A1 (en) | 2008-01-10 | 2009-07-16 | Coloplast A/S | A pressure sensitive adhesive composition comprising a water soluble compound |
| EP2286814B1 (en) | 2008-05-15 | 2013-10-16 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal preparation containing palonosetron |
| DE102008060203A1 (de) | 2008-12-07 | 2010-06-10 | Dietrich Wilhelm Schacht | Wirkstoffstabilisierende flächenförmige Vorrichtung |
| CA2746442A1 (en) * | 2008-12-11 | 2010-06-17 | A.P. Pharma, Inc. | Methods for enhancing stability of polyorthoesters and their formulations |
| EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| SMT202400353T1 (it) | 2009-12-22 | 2024-11-15 | UCB Biopharma SRL | Polivinilpirrolidone per la stabilizzazione di una dispersione solida della forma non cristallina della rotigotina |
| US8563031B2 (en) | 2010-05-27 | 2013-10-22 | Absize, Inc. | Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith |
| CN102499906B (zh) * | 2011-10-12 | 2013-04-17 | 长春健欣生物医药科技开发有限公司 | 一种罗替戈汀盐酸盐或自由碱成膜凝胶制剂及其制备方法 |
| WO2013075822A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system (tts) with rotigotine |
| DE102012013439A1 (de) | 2012-07-03 | 2014-01-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor |
| DE102011119043A1 (de) | 2011-11-22 | 2013-05-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TDS) mit Rotigotin |
| DE102012013421A1 (de) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TTS) mit Rotigotin |
| JP2015506978A (ja) * | 2012-02-08 | 2015-03-05 | ダウ コーニング コーポレーションDow Corning Corporation | ヘルスケア有効成分の送達用シリコーンエマルション |
| WO2014198422A1 (de) | 2013-06-14 | 2014-12-18 | Tesa Labtec Gmbh | Transdermales therapiesystem (tts) mit rotigotin |
| US20150068707A1 (en) * | 2013-09-09 | 2015-03-12 | Nec Corporation | Electronic component cooling apparatus |
| ES2900255T3 (es) * | 2017-09-04 | 2022-03-16 | Lts Lohmann Therapie Systeme Ag | Sistema de administración transdérmica que incluye un emulsionante |
| KR102731700B1 (ko) | 2018-10-24 | 2024-11-15 | 에스케이케미칼 주식회사 | 비결정 로티고틴 함유 조성물 및 이의 제조 방법 |
| PT3854388T (pt) | 2020-01-24 | 2023-12-11 | Luye Pharma Switzerland Ag | Sistema terapêutico transdérmico com o princípio ativo rotigotina e pelo menos um adesivo de silicone não resistente a aminas |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4373519A (en) * | 1981-06-26 | 1983-02-15 | Minnesota Mining And Manufacturing Company | Composite wound dressing |
| US4882352A (en) * | 1986-07-28 | 1989-11-21 | Nelson Research & Development Co. | Method for treating schizophrenia |
| US4559222A (en) * | 1983-05-04 | 1985-12-17 | Alza Corporation | Matrix composition for transdermal therapeutic system |
| DE3333240A1 (de) * | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
| US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| US4885308A (en) * | 1984-08-13 | 1989-12-05 | Nelson Research & Development Co. | Method and compositions for treatment of parkinsonism syndrome in mammals |
| US4996226A (en) * | 1984-08-13 | 1991-02-26 | Whitby Research, Inc. | Method and compositions for treatment of parkinsonism syndrome in mammels |
| US4904247A (en) * | 1984-08-31 | 1990-02-27 | Kendall Company | Pressure-sensitive hydrophilic laminate structures for use in wound dressing, transdermal and topical drug delivery |
| EP0186019B1 (de) * | 1984-12-22 | 1993-10-06 | Schwarz Pharma Ag | Wirkstoffpflaster |
| US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US4826686A (en) * | 1985-12-14 | 1989-05-02 | Boehringer Ingelheim Kg | Therapeutic system |
| US4880633A (en) * | 1986-03-12 | 1989-11-14 | Merck & Co., Inc. | Transdermal drug delivery system |
| EP0249475A3 (en) * | 1986-06-13 | 1989-10-11 | Alza Corporation | Delayed percutaneous delivery |
| DD294867A5 (de) * | 1986-07-29 | 1991-10-17 | Gummiwerke Thueringen Gmbh | Verfahren zur herstellung von latextauchartikeln mit fibrinolytischer depotwirkung |
| US4737410A (en) * | 1986-11-28 | 1988-04-12 | Minnesota Mining And Manufacturing Company | Polyalkyloxazoline-reinforced acrylic pressure-sensitive adhesive composition |
| US4906463A (en) * | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
| EP0273700B1 (en) * | 1986-12-25 | 1992-03-04 | Sumitomo Electric Industries Limited | Process for producing a medical vinyl chloride resin material |
| US4857313A (en) * | 1987-05-28 | 1989-08-15 | Warner-Lambert Company | Transdermal drug delivery device comprising copolymers of N-morpholinoethyl methacrylate and 2-hydroxylmethacrylate |
| US4814173A (en) * | 1987-09-08 | 1989-03-21 | Warner-Lambert Company | Silicone elastomer transdermal matrix system |
| US5035894A (en) * | 1987-10-15 | 1991-07-30 | Dow Corning Corporation | Controlled release compositions and transdermal drug delivery device |
| US4898920A (en) * | 1987-10-15 | 1990-02-06 | Dow Corning Corporation | Adhesive compositions, controlled release compositions and transdermal delivery device |
| US5071645A (en) * | 1987-10-19 | 1991-12-10 | Ppg Industries, Inc. | Process of producing an active agent delivery device |
| US4959208A (en) * | 1987-10-19 | 1990-09-25 | Ppg Industries, Inc. | Active agent delivery device |
| US5019378A (en) * | 1987-12-29 | 1991-05-28 | Cuno, Incorporated | Elastomeric composition containing therapeutic agents and articles manufactured therefrom |
| JPH01186823A (ja) * | 1988-01-21 | 1989-07-26 | Dow Corning Kk | 薬物透過性物質の製造方法 |
| US4898734A (en) * | 1988-02-29 | 1990-02-06 | Massachusetts Institute Of Technology | Polymer composite for controlled release or membrane formation |
| US5300291A (en) * | 1988-03-04 | 1994-04-05 | Noven Pharmaceuticals, Inc. | Method and device for the release of drugs to the skin |
| US5118692A (en) * | 1988-04-08 | 1992-06-02 | Whitby Research, Inc. | Penetration enhances for transdermal delivery of systemic agents |
| US5118676A (en) * | 1988-04-08 | 1992-06-02 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
| US4996199A (en) * | 1988-04-08 | 1991-02-26 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
| US5166341A (en) * | 1988-07-29 | 1992-11-24 | Dainippon Pharmaceutical Co., Ltd. | 6-amino-1,4-hexahydro-1H-diazepine derivatives |
| NZ230068A (en) * | 1988-07-29 | 1991-07-26 | Dainippon Pharmaceutical Co | Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions |
| US5240995A (en) * | 1989-02-09 | 1993-08-31 | Alza Corporation | Electrotransport adhesive |
| DE3910543A1 (de) * | 1989-04-01 | 1990-10-11 | Lohmann Therapie Syst Lts | Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung |
| US5028435A (en) * | 1989-05-22 | 1991-07-02 | Advanced Polymer Systems, Inc. | System and method for transdermal drug delivery |
| US5225407A (en) * | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| JP2849937B2 (ja) * | 1990-04-18 | 1999-01-27 | 日東電工株式会社 | 医療用貼付剤 |
| JP2875611B2 (ja) * | 1990-08-29 | 1999-03-31 | エーザイ株式会社 | ケイ酸カルシウム含有外用剤 |
| US5232702A (en) * | 1991-07-22 | 1993-08-03 | Dow Corning Corporation | Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices |
| US5300299A (en) * | 1991-07-22 | 1994-04-05 | Dow Corning Corporation | Silicone pressure sensitive adhesive containing alkylmethylsiloxane wax and related methods and devices |
| US5989586A (en) * | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
| EP0760238B1 (en) * | 1994-05-18 | 2002-04-17 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneously administrable preparation for treating urination disorder |
-
1993
- 1993-04-30 US US08/056,076 patent/US5989586A/en not_active Expired - Lifetime
- 1993-10-05 EP EP93923258A patent/EP0662822B1/en not_active Expired - Lifetime
- 1993-10-05 AT AT93923258T patent/ATE198420T1/de not_active IP Right Cessation
- 1993-10-05 JP JP6509398A patent/JPH08504757A/ja active Pending
- 1993-10-05 PT PT93923258T patent/PT662822E/pt unknown
- 1993-10-05 CA CA002145631A patent/CA2145631C/en not_active Expired - Lifetime
- 1993-10-05 WO PCT/US1993/009510 patent/WO1994007468A1/en active IP Right Grant
- 1993-10-05 DE DE69329825T patent/DE69329825T2/de not_active Expired - Lifetime
- 1993-10-05 ES ES93923258T patent/ES2155073T3/es not_active Expired - Lifetime
- 1993-10-05 AU AU53211/94A patent/AU5321194A/en not_active Abandoned
- 1993-10-05 DK DK93923258T patent/DK0662822T3/da active
- 1993-10-05 CN CN93118244A patent/CN1089469A/zh active Pending
- 1993-10-27 TW TW082108949A patent/TW252919B/zh active
-
1995
- 1995-06-07 US US08/474,693 patent/US5840336A/en not_active Expired - Lifetime
-
2001
- 2001-03-23 GR GR20010400471T patent/GR3035626T3/el unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457095C (zh) * | 2001-05-08 | 2009-02-04 | 施瓦茨制药有限公司 | 用于治疗帕金森氏病的改良经皮治疗系统 |
| CN102172351B (zh) * | 2001-05-08 | 2013-07-17 | 优时比制药有限公司 | 引起高罗替高汀血浆水平的用于治疗帕金森氏病的透皮治疗系统 |
| CN100558350C (zh) * | 2002-07-30 | 2009-11-11 | 施瓦茨制药有限公司 | 改良透皮递药系统 |
Also Published As
| Publication number | Publication date |
|---|---|
| PT662822E (pt) | 2001-04-30 |
| TW252919B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1995-08-01 |
| CA2145631A1 (en) | 1994-04-14 |
| GR3035626T3 (en) | 2001-06-29 |
| ATE198420T1 (de) | 2001-01-15 |
| DE69329825D1 (de) | 2001-02-08 |
| WO1994007468A1 (en) | 1994-04-14 |
| EP0662822B1 (en) | 2001-01-03 |
| EP0662822A4 (en) | 1996-08-07 |
| ES2155073T3 (es) | 2001-05-01 |
| US5989586A (en) | 1999-11-23 |
| AU5321194A (en) | 1994-04-26 |
| CA2145631C (en) | 2004-02-10 |
| EP0662822A1 (en) | 1995-07-19 |
| DE69329825T2 (de) | 2001-06-13 |
| JPH08504757A (ja) | 1996-05-21 |
| DK0662822T3 (da) | 2001-01-29 |
| US5840336A (en) | 1998-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1089469A (zh) | 用于持续释放药物的传送装置的二相基材 | |
| JP5695562B2 (ja) | 安定化された経皮薬物送達システム | |
| US7413747B2 (en) | Transdermal therapeutic system for treating Parkinsonism | |
| US4883669A (en) | Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration | |
| CN1731995B (zh) | 用于经皮给药d2促进素碱的器具 | |
| US20180078512A1 (en) | Transdermal delivery of cannabidiol with other active moieties including cannabinoids | |
| CN101032474A (zh) | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 | |
| JP5069402B2 (ja) | フェンタニル懸濁液をベースにしたシリコーン系粘着剤製剤及びフェンタニルを経皮送達するための装置 | |
| CN1507918A (zh) | 透皮促进剂甘油三醋酸酯 | |
| CN1784222A (zh) | 具有包含辣椒碱的聚硅氧烷基质的治疗贴剂 | |
| CN1466452A (zh) | 用于经皮传递芬太尼的组合物 | |
| CN1298326C (zh) | 芬太尼经皮外用贴剂 | |
| ES2657887T3 (es) | Preparación adhesiva | |
| CN1671375A (zh) | 施用罗替戈汀的改良透皮递药系统 | |
| IE65520B1 (en) | Transdermal therapeutic system exhibiting an increased active substance flow and process for the production thereof | |
| CN1545407A (zh) | 含有活性物质芬太尼的透皮治疗体系(tts) | |
| CN1349794A (zh) | 经皮吸收制剂 | |
| JP4466977B2 (ja) | 経皮的治療システム | |
| CN1135971C (zh) | 含有5-羟色胺受体拮抗剂的经皮给药制剂 | |
| CN1905866A (zh) | 妥洛特罗贴剂 | |
| HK1052472A1 (zh) | Lasofoxifene的经皮转运 | |
| EP0235259B1 (en) | Novel transdermal anti-anginal pharmaceutical dosage unit and process for its administration | |
| JP2004538300A (ja) | 皮膚又は粘膜上の適用に関する有効成分を含有する粒子を含む剤形 | |
| JP3497309B2 (ja) | 貼付剤 | |
| CN1929827A (zh) | 包含至少一种脂肪酸的用于二氢吡啶类钙拮抗剂的经皮递送装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination |